Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
AC Immune S.A. (ACIU)
USD2.38
-0.04 (-1.45%)
CH NASDAQ Healthcare Biotechnology
Address
Building B 1015
Lausanne, CH
Lausanne, CH
CEO
Andrea Pfeifer
Website
acimmune.com
IPO
2016-09-23
CIK 1651625 ISIN CH0329023102
Description
AC Immune S.A. is a biotech firm operating at the clinical stage, dedicated to pioneering, formulating, and advancing therapeutic agents and diagnostic tools. Its core mission is addressing neurodegenerative conditions rooted in protein misfolding, both preventatively and therapeutically. Leveraging its proprietary SupraAntigen and Morphomer platforms, the company engineers a range of vaccines, antibodies, and small molecules specifically designed to engage with aberrantly folded proteins implicated across various neurodegenerative disorders. Its pipeline features Crenezumab, a humanized, conformation-specific monoclonal antibody currently undergoing a Phase II clinical prevention trial for Alzheimer's disease (AD). Additionally, AC Immune is advancing ACI-24, an anti-Abeta vaccine candidate, which is in Phase II clinical evaluation for AD and has successfully completed a Phase Ib study for Down syndrome. Other key candidates include ACI-35, an anti-Tau vaccine candidate that has finished Phase Ib clinical assessment, and a Tau-positron emission tomography (PET) imaging tracer, also in Phase II development. Furthermore, the company is engaged in the research and development of small molecule inhibitors to prevent Tau aggregation, targeting AD and various NeuroOrphan indications. Early-stage efforts include discovery and preclinical programs for a spectrum of neurodegenerative diseases, encompassing diagnostic agents aimed at TDP-43, alpha-synuclein, and NLRP3. The company maintains strategic partnerships and licensing agreements with key industry players such as Genentech, Inc., Biogen International GmbH, Janssen Pharmaceuticals, Inc., Life Molecular Imaging SA, Eli Lilly and Company, and WuXi Biologics. Founded in 2003, AC Immune S.A. is headquartered in Lausanne, Switzerland.
News Sentiment (7d)
Based on only 1 article — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD2.38
-0.04 (-1.45%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
293.7K
Beta
1.56
Float Shares
61.55M
Free Float %
60.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.12% | -5.78% | -16.06% | -7.36% | -14.24% | -11.78% | +76.43% | +31.90% | -55.18% | -82.31% | -82.31% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (9 ratings, all time)
Buy
Price Targets & DCF
Current price
2.38
Low
7.00
+194.7%
Consensus
7.00
+194.7%
Median
7.00
+194.7%
High
7.00
+194.7%
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 4 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | 1 |
7.00
+194.7%
|
| Last Year | 1 |
7.00
+194.7%
|
| All Time | 3 |
8.33
+250.7%
|
Quality scores
Altman Z-Score
-5.01
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-86.9% Q1'26: +13.0% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-37.3% Q1'26: +21.1% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-2,106.7% Q1'26: -1,479.4% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-1,966.3% Q1'26: -1,316.9% (vs Q1'25)
-
ROIC Biotechnology: -16.1%— Q1'26: +151.3% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+1.1% ★ Q1'26: -1.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.07× Q1'26: -0.07× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 2 EPS Ana. |
Dec 2027 3 Rev. Ana. 2 EPS Ana. |
Dec 2028 3 Rev. Ana. 3 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
23.21M
est: 24.65M (-5.8%)
|
20.26M
est: 21.15M (-4.2%)
|
7.19M
est: 48.39M (-85.1%)
|
110.46M
est: 112.82M (-2.1%)
|
15.43M
est: 15.63M (-1.3%)
|
—
est: 28.25M (-100.0%)
|
3.94M
est: 5.58M (-29.5%)
|
14.80M
est: 13.93M (+6.2%)
|
27.31M
est: 27.09M (+0.8%)
|
3.57M
est: 4.34M (-17.7%)
|
32.20M
12.18M – 52.18M
+642.0% YoY
|
93.28M
61.80M – 124.74M
+189.7% YoY
|
119.79M
76.45M – 175.46M
+28.4% YoY
|
109.93M
70.15M – 161.01M
-8.2% YoY
|
119.22M
76.09M – 174.63M
+8.5% YoY
|
| EBITDA |
-6.81M
est: -14.79M (+54.0%)
|
-22.54M
est: -12.69M (-77.6%)
|
-49.66M
est: -29.03M (-71.0%)
|
45.81M
est: -67.69M (+167.7%)
|
-59.73M
est: -9.38M (-537.0%)
|
-70.01M
est: -16.95M (-313.0%)
|
-68.03M
est: -3.35M (-1,930.5%)
|
-51.83M
est: -8.36M (-520.0%)
|
-48.62M
est: -16.25M (-199.1%)
|
-67.75M
est: -2.60M (-2,502.4%)
|
-19.32M
-31.31M – -7.31M
-642.0% YoY
|
-55.97M
-74.85M – -37.08M
-189.7% YoY
|
-71.88M
-105.28M – -45.87M
-28.4% YoY
|
-65.96M
-96.61M – -42.09M
+8.2% YoY
|
-71.53M
-104.78M – -45.65M
-8.5% YoY
|
| EBIT |
-7.09M
est: -14.79M (+52.1%)
|
-26.26M
est: -12.69M (-107.0%)
|
-50.62M
est: -29.03M (-74.4%)
|
44.54M
est: -67.69M (+165.8%)
|
-61.26M
est: -9.38M (-553.4%)
|
-72.41M
est: -16.95M (-327.2%)
|
-70.39M
est: -3.35M (-2,000.9%)
|
-54.05M
est: -8.36M (-546.5%)
|
-50.78M
est: -16.25M (-212.4%)
|
-70.26M
est: -2.60M (-2,598.5%)
|
-19.32M
-31.31M – -7.31M
-642.0% YoY
|
-55.97M
-74.85M – -37.08M
-189.7% YoY
|
-71.88M
-105.28M – -45.87M
-28.4% YoY
|
-65.96M
-96.61M – -42.09M
+8.2% YoY
|
-71.53M
-104.78M – -45.65M
-8.5% YoY
|
| Net Income |
-7.10M
est: -19.06M (+62.8%)
|
-26.41M
est: -51.44M (+48.7%)
|
-50.95M
est: -20.54M (-148.0%)
|
45.44M
est: 68.30M (-33.5%)
|
-61.92M
est: -82.30M (+24.8%)
|
-73.00M
est: -63.04M (-15.8%)
|
-70.75M
est: -87.26M (+18.9%)
|
-54.23M
est: -54.44M (+0.4%)
|
-50.92M
est: -53.70M (+5.2%)
|
-70.45M
est: -53.05M (-32.8%)
|
-26.74M
-43.47M – -26.39M
+49.6% YoY
|
15.13M
4.08M – 38.14M
+156.6% YoY
|
5.30M
-711.96M – 773.37M
-65.0% YoY
|
37.17M
19.68M – 59.62M
+601.3% YoY
|
40.81M
21.62M – 65.47M
+9.8% YoY
|
| SGA |
4.73M
est: 28.45M (-83.4%)
|
6.27M
est: 24.41M (-74.3%)
|
7.56M
est: 55.85M (-86.5%)
|
16.06M
est: 130.21M (-87.7%)
|
18.56M
est: 18.04M (+2.9%)
|
10.88M
est: 32.61M (-66.6%)
|
9.58M
est: 6.44M (+48.7%)
|
10.58M
est: 21.82M (-51.5%)
|
11.43M
est: 42.42M (-73.0%)
|
11.65M
est: 6.79M (+71.5%)
|
50.42M
19.07M – 81.71M
+642.0% YoY
|
146.06M
96.78M – 195.33M
+189.7% YoY
|
187.58M
119.71M – 274.75M
+28.4% YoY
|
172.13M
109.85M – 252.12M
-8.2% YoY
|
186.69M
119.14M – 273.45M
+8.5% YoY
|
| EPS |
-0.14
est: -0.19 (+26.8%)
|
-0.46
est: -0.52 (+10.9%)
|
-0.82
est: -0.21 (-297.9%)
|
0.64
est: 0.69 (-6.6%)
|
-0.86
est: -0.83 (-4.2%)
|
-0.97
est: -0.63 (-53.4%)
|
-0.85
est: -0.88 (+2.9%)
|
-0.64
est: -0.59 (-8.9%)
|
-0.51
est: -0.54 (+5.1%)
|
-0.70
est: -0.53 (-31.6%)
|
-0.35
-0.43 – -0.26
+34.3% YoY
|
0.21
0.04 – 0.38
+160.0% YoY
|
0.50
-7.07 – 7.68
+137.5% YoY
|
0.37
0.20 – 0.59
-25.9% YoY
|
0.41
0.21 – 0.65
+9.8% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-04 | BTIG | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-01 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-76.98M
OE per share TTM
-0.77
Owner's Yield
-28.16%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
28.2%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
6
Total invested
104.6K
Insider transactions (90d)
0
Beneficial owners (>5%)
47
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | DH-Capital GmbH & Co. KG | 18.04M | 25.10% | — | 18.04M | — | 18.04M | OO | Germany | 2021-02-12 | ↗ |
| 2 | Daniel Hopp | 18.04M | 25.10% | — | 18.04M | — | 18.04M | IN | Germany | 2021-02-12 | ↗ |
| 3 | Dietmar Hopp | 18.04M | 25.10% | — | 18.04M | — | 18.04M | IN | Germany | 2021-02-12 | ↗ |
| 4 | Dr. Mathias Hothum | 18.04M | 25.10% | — | 18.04M | — | 18.04M | IN | Germany | 2021-02-12 | ↗ |
| 5 | OH Beteiligungen GmbH & Co. KG | 18.04M | 25.10% | — | 18.04M | — | 18.04M | OO | Germany | 2021-02-12 | ↗ |
| 6 | Oliver Hopp | 18.04M | 25.10% | — | 18.04M | — | 18.04M | IN | Germany | 2021-02-12 | ↗ |
| 7 | Prof. Dr. Christof Hettich | 18.04M | 25.10% | — | 18.04M | — | 18.04M | IN | Germany | 2021-02-12 | ↗ |
| 8 | Prof. Dr. Friedrich von Bohlen und Halbach | 18.04M | 25.10% | — | 18.04M | — | 18.04M | IN | Germany | 2021-02-12 | ↗ |
| 9 | dievini Hopp BioTech holding GmbH & Co. KG | 18.04M | 25.10% | — | 18.04M | — | 18.04M | OO | Germany | 2021-02-12 | ↗ |
| 10 | Athos KG | 8.62M | 10.10% | — | — | — | 7.11M | PN | Germany | 2021-08-05 | ↗ |
| 11 | FCP Biotech Holding GmbH | 8.62M | 10.10% | — | — | — | 7.11M | CO | Germany | 2021-08-05 | ↗ |
| 12 | FCPB Affi GmbH | 8.62M | 10.10% | — | — | — | 7.11M | CO | Germany | 2021-08-05 | ↗ |
| 13 | First Capital Partner GmbH | 8.62M | 10.10% | — | — | — | 7.11M | CO | Germany | 2021-08-05 | ↗ |
| 14 | Santo Holding (Deutschland) GmbH | 8.62M | 10.10% | — | — | — | 7.11M | PN | Germany | 2021-08-05 | ↗ |
| 15 | Santo Venture Capital GmbH | 8.62M | 10.10% | — | — | — | 7.11M | CO | Germany | 2021-08-05 | ↗ |
| 16 | Wolfgang Egger | 8.62M | 10.10% | — | — | — | 7.11M | IN | Germany | 2021-08-05 | ↗ |
| 17 | we holding GmbH & Co. KG | 8.62M | 10.10% | — | — | — | 7.11M | PN | Germany | 2021-08-05 | ↗ |
| 18 | Affiris AG | 7.11M | 8.46% | — | — | — | — | CO | Germany | 2021-08-05 | ↗ |
| 19 | Dr. Matthias Hallweger | 7.11M | 8.46% | — | — | — | 7.11M | IN | Germany | 2021-08-05 | ↗ |
| 20 | HMW Emissionshaus AG | 7.11M | 8.46% | — | — | — | 7.11M | CO | Germany | 2021-08-05 | ↗ |
| 21 | HMW Komplementär GmbH | 7.11M | 8.46% | — | — | — | 7.11M | CO | Germany | 2021-08-05 | ↗ |
| 22 | HMW Verwaltungs GmbH | 7.11M | 8.46% | — | — | — | 7.11M | CO | Germany | 2021-08-05 | ↗ |
| 23 | MIG Asset Trust GmbH | 7.11M | 8.46% | — | — | — | 7.11M | CO | Germany | 2021-08-05 | ↗ |
| 24 | MIG GmbH & Co. Fonds 11 KG i.L. | 7.11M | 8.46% | — | — | — | 7.11M | PN | Germany | 2021-08-05 | ↗ |
| 25 | MIG GmbH & Co. Fonds 12 geschlossene Investment-KG | 7.11M | 8.46% | — | — | — | 7.11M | PN | Germany | 2021-08-05 | ↗ |
| 26 | MIG GmbH & Co. Fonds 13 geschlossene Investment-KG | 7.11M | 8.46% | — | — | — | 7.11M | PN | Germany | 2021-08-05 | ↗ |
| 27 | MIG GmbH & Co. Fonds 15 geschlossene Investment-KG | 7.11M | 8.46% | — | — | — | 7.11M | PN | Germany | 2021-08-05 | ↗ |
| 28 | MIG GmbH & Co. Fonds 4 KG | 7.11M | 8.46% | — | — | — | 7.11M | PN | Germany | 2021-08-05 | ↗ |
| 29 | MIG GmbH & Co. Fonds 5 KG i.L. | 7.11M | 8.46% | — | — | — | 7.11M | PN | Germany | 2021-08-05 | ↗ |
| 30 | MIG GmbH & Co. Fonds 7 KG i.L. | 7.11M | 8.46% | — | — | — | 7.11M | PN | Germany | 2021-08-05 | ↗ |
| 31 | MIG Komplementär GmbH | 7.11M | 8.46% | — | — | — | 7.11M | CO | Germany | 2021-08-05 | ↗ |
| 32 | MIG Verwaltungs AG | 7.11M | 8.46% | — | — | — | 7.11M | CO | Germany | 2021-08-05 | ↗ |
| 33 | Michael Motschmann | 7.11M | 8.46% | — | — | — | 7.11M | CO | Germany | 2021-08-05 | ↗ |
| 34 | BVF Inc. | 7.06M | 9.70% | — | — | — | 7.06M | CO | — | 2022-02-14 | ↗ |
| 35 | BVF Partners L.P. | 7.06M | 9.70% | — | — | — | 7.06M | IA, PN | — | 2022-02-14 | ↗ |
| 36 | Mark N. Lampert | 7.06M | 9.70% | — | — | — | 7.06M | IN | — | 2022-02-14 | ↗ |
| 37 | BVF GP Holdings LLC | 6.51M | 9.00% | — | — | — | 6.51M | OO | — | 2022-02-14 | ↗ |
| 38 | BVF I GP LLC | 3.65M | 5.00% | — | — | — | 3.65M | OO | — | 2022-02-14 | ↗ |
| 39 | Biotechnology Value Fund, L.P. | 3.65M | 5.00% | — | — | — | 3.65M | PN | — | 2022-02-14 | ↗ |
| 40 | Eli Lilly and Company | 3.62M | 5.00% | 3.62M | — | 3.62M | — | CO | — | 2021-02-12 | ↗ |
| 41 | BVF II GP LLC | 2.86M | 3.90% | — | — | — | 2.86M | OO | — | 2022-02-14 | ↗ |
| 42 | Biotechnology Value Trading Fund II, L.P. | 2.86M | 3.90% | — | — | — | 2.86M | PN | — | 2022-02-14 | ↗ |
| 43 | EcoR1 Capital, LLC | 749.6K | 11.00% | — | 749.6K | — | 749.6K | IA, OO | Delaware | 2022-02-14 | ↗ |
| 44 | Oleg Nodelman | 749.6K | 11.00% | — | 749.6K | — | 749.6K | HC, IN | United States | 2022-02-14 | ↗ |
| 45 | EcoR1 Capital Fund Qualified, L.P. | 664.3K | 11.00% | — | 664.3K | — | 664.3K | PN | Delaware | 2022-02-14 | ↗ |
| 46 | BVF Partners OS Ltd. | 420.2K | 1.00% | — | — | — | 420.2K | CO | — | 2022-02-14 | ↗ |
| 47 | Biotechnology Value Trading Fund OS LP | 420.2K | 1.00% | — | — | — | 420.2K | PN | — | 2022-02-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
6
-41 vs prev Q
New positions
1
Closed positions
36
Increased
3
Reduced
1
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | BVF INC/IL | 19.82M +— (+0.0%) | 62.24M +5.0M (+8.7%) | 20.00% +0.302 pp | 2.10% -0.227 pp | USD5.00 -37.2% | 30 qtrs — |
| 2 | WELLS FARGO & COMPANY/MN | 1.01M -4.2K (-0.4%) | 3.16M +239.3K (+8.2%) | 1.02% +0.011 pp | 0.00% +0.000 pp | USD3.64 -13.7% | 28 qtrs — |
| 3 | MILLENNIUM MANAGEMENT LLC | 933.3K +38.8K (+4.3%) | 2.93M +345.5K (+13.4%) | 0.94% +0.053 pp | 0.00% +0.000 pp | USD2.86 +9.8% | 7 qtrs — |
| 4 | RENAISSANCE TECHNOLOGIES LLC | 668.9K -101.6K (-13.2%) | 2.10M -126.3K (-5.7%) | 0.67% -0.091 pp | 0.00% +0.000 pp | USD4.54 -30.8% | 35 qtrs — |
| 5 | BLACKROCK, INC. | 502.2K +90.3K (+21.9%) | 1.58M +386.6K (+32.5%) | 0.51% +0.097 pp | 0.00% +0.000 pp | USD3.66 -14.2% | 6 qtrs — |
| 6 | ACADIAN ASSET MANAGEMENT LLC | 464.7K +51.5K (+12.5%) | 1.44M +262.0K (+22.2%) | 0.47% +0.058 pp | 0.00% +0.000 pp | USD2.49 +26.1% | 6 qtrs — |
| 7 | ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 375.6K +375.6K (+100.0%) | 1.18M +1.2M (+100.0%) | 0.38% +0.379 pp | 0.00% +0.001 pp | USD3.14 +0.0% | 1 qtrs NEW |
| 8 | NORTHERN TRUST CORP | 282.0K +— (+0.0%) | 885.3K +70.5K (+8.7%) | 0.28% +0.004 pp | 0.00% +0.000 pp | USD2.69 +16.7% | 5 qtrs — |
| 9 | DIMENSIONAL FUND ADVISORS LP | 213.5K +36.4K (+20.5%) | 670.4K +157.0K (+30.6%) | 0.22% +0.039 pp | 0.00% +0.000 pp | USD2.43 +29.2% | 12 qtrs — |
| 10 | UBS GROUP AG | 194.3K +177.9K (+1,083.3%) | 610.3K +562.8K (+1,185.7%) | 0.20% +0.180 pp | 0.00% +0.000 pp | USD3.13 +0.3% | 35 qtrs — |
| 11 | MARSHALL WACE, LLP | 186.7K +186.7K (+100.0%) | 586.3K +586.3K (+100.0%) | 0.19% +0.188 pp | 0.00% +0.001 pp | USD3.14 +0.0% | 6 qtrs — |
| 12 | DAUNTLESS INVESTMENT GROUP, LLC | 115.7K +115.7K (+100.0%) | 363.2K +363.2K (+100.0%) | 0.12% +0.117 pp | 0.29% +0.288 pp | USD3.14 +0.0% | 1 qtrs NEW |
| 13 | MORGAN STANLEY | 94.3K +2.3K (+2.5%) | 296.2K +30.3K (+11.4%) | 0.10% +0.004 pp | 0.00% +0.000 pp | USD3.56 -11.8% | 33 qtrs — |
| 14 | TWO SIGMA INVESTMENTS, LP | 87.9K +71.1K (+423.9%) | 276.0K +227.5K (+469.2%) | 0.09% +0.072 pp | 0.00% +0.000 pp | USD2.93 +7.2% | 7 qtrs — |
| 15 | GEODE CAPITAL MANAGEMENT, LLC | 63.6K +— (+0.0%) | 199.7K +15.9K (+8.7%) | 0.06% +0.001 pp | 0.00% +0.000 pp | USD6.66 -52.9% | 38 qtrs — |
| 16 | CITADEL ADVISORS LLC | 50.5K +50.5K (+100.0%) | 158.6K +158.6K (+100.0%) | 0.05% +0.051 pp | 0.00% +0.000 pp | USD3.14 +0.0% | 1 qtrs NEW |
| 17 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 38.4K +38.4K (+100.0%) | 120.6K +120.6K (+100.0%) | 0.04% +0.039 pp | 0.00% +0.000 pp | USD3.14 +0.0% | 1 qtrs NEW |
| 18 | POINT72 ASSET MANAGEMENT, L.P. | 27.9K +27.9K (+100.0%) | 87.6K +87.6K (+100.0%) | 0.03% +0.028 pp | 0.00% +0.000 pp | USD3.14 +0.0% | 1 qtrs NEW |
| 19 | BANK OF AMERICA CORP /DE/ | 21.5K +15.6K (+262.9%) | 67.4K +50.3K (+294.3%) | 0.02% +0.016 pp | 0.00% +0.000 pp | USD2.98 +5.4% | 9 qtrs — |
| 20 | JANE STREET GROUP, LLC | 21.4K +21.4K (+100.0%) | 67.2K +67.2K (+100.0%) | 0.02% +0.022 pp | 0.00% +0.000 pp | USD3.14 +0.0% | 1 qtrs NEW |
| 21 | GOLDMAN SACHS GROUP INC | 18.6K +5.9K (+46.9%) | 58.3K +21.7K (+59.6%) | 0.02% +0.006 pp | 0.00% +0.000 pp | USD2.49 +26.1% | 3 qtrs — |
| 22 | CHINA UNIVERSAL ASSET MANAGEMENT CO., LTD. | 16.4K -1.2K (-7.0%) | 51.4K +513.0 (+1.0%) | 0.02% -0.001 pp | 0.00% 0.000 pp | USD3.71 -15.4% | 9 qtrs — |
| 23 | SEI INVESTMENTS CO | 15.9K +— (+0.0%) | 49.9K +4.0K (+8.7%) | 0.02% +0.000 pp | 0.00% +0.000 pp | USD1.87 +67.9% | 4 qtrs — |
| 24 | — | 12.9K +12.9K (+100.0%) | 40.5K +40.5K (+100.0%) | 0.01% +0.013 pp | 0.00% +0.001 pp | USD3.14 +0.0% | 1 qtrs NEW |
| 25 | QUINN OPPORTUNITY PARTNERS LLC | 10.1K +— (+0.0%) | 31.7K +2.5K (+8.7%) | 0.01% +0.000 pp | 0.00% -0.001 pp | USD2.70 +16.3% | 5 qtrs — |
| 26 | SILVERBERG BERNSTEIN CAPITAL MANAGEMENT LLC | 10.0K +— (+0.0%) | 31.3K +2.4K (+8.3%) | 0.01% +0.000 pp | 0.02% +0.001 pp | USD3.98 -21.1% | 7 qtrs — |
| 27 | JPMORGAN CHASE & CO | 8.7K +1.5K (+20.1%) | 27.4K +6.4K (+30.5%) | 0.01% +0.002 pp | 0.00% +0.000 pp | USD3.13 +0.3% | 19 qtrs — |
| 28 | BANQUE CANTONALE VAUDOISE | 7.9K -10.5K (-57.2%) | 25.0K -28.0K (-52.8%) | 0.01% -0.010 pp | 0.00% -0.001 pp | USD1.87 +67.9% | 4 qtrs — |
| 29 | TOWER RESEARCH CAPITAL LLC (TRC) | 6.2K +2.9K (+86.5%) | 19.4K +9.8K (+102.7%) | 0.01% +0.003 pp | 0.00% +0.000 pp | USD2.92 +7.5% | 30 qtrs — |
| 30 | MIRAE ASSET GLOBAL INVESTMENTS CO., LTD. | 4.9K +997.0 (+25.7%) | 15.3K +4.1K (+36.6%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD3.55 -11.5% | 7 qtrs — |
| 31 | CITIGROUP INC | 2.8K +870.0 (+45.1%) | 8.8K +3.2K (+57.6%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD3.20 -1.9% | 9 qtrs — |
| 32 | BARCLAYS PLC | 2.7K +2.2K (+451.2%) | 8.5K +6.6K (+357.9%) | 0.00% +0.002 pp | 0.00% +0.000 pp | USD3.03 +3.6% | 6 qtrs — |
| 33 | BNP PARIBAS ARBITRAGE, SNC | 2.5K -323.0 (-11.5%) | 7.8K -314.0 (-3.9%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD3.02 +4.0% | 9 qtrs — |
| 34 | GF FUND MANAGEMENT CO. LTD. | 2.0K -188.0 (-8.7%) | 6.2K -50.0 (-0.8%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD2.57 +22.2% | 5 qtrs — |
| 35 | ACTIVEST WEALTH MANAGEMENT | 1.0K +— (+0.0%) | 3.1K +250.0 (+8.7%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD3.98 -21.1% | 7 qtrs — |
| 36 | ROCKEFELLER CAPITAL MANAGEMENT L.P. | 1.0K +— (+0.0%) | 3.1K +250.0 (+8.7%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.89 +8.7% | 2 qtrs — |
| 37 | ROYAL BANK OF CANADA | 858.00 -950.0 (-52.5%) | 2.0K -3.0K (-60.0%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD3.29 -4.6% | 22 qtrs — |
| 38 | SBI SECURITIES CO., LTD. | 547.00 -1.0 (-0.2%) | 1.7K +134.0 (+8.5%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.67 +17.6% | 5 qtrs — |
| 39 | ADVISOR GROUP HOLDINGS, INC. | 221.00 -30.0 (-12.0%) | 693.00 -31.0 (-4.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.03 +54.7% | 3 qtrs — |
| 40 | STRENGTHENING FAMILIES & COMMUNITIES, LLC | 200.00 +— (+0.0%) | 628.00 +50.0 (+8.7%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.96 +6.1% | 11 qtrs — |
| 41 | ASSENAGON ASSET MANAGEMENT S.A. | — -189.9K (-100.0%) | — -548.8K (-100.0%) | 0.00% -0.189 pp | 0.00% -0.001 pp | USD— | 2 qtrs SOLD |
| 42 | SIMPLEX TRADING, LLC | — -3.3K (-100.0%) | — -9.0K (-100.0%) | 0.00% -0.003 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 43 | PRIVATE ADVISOR GROUP, LLC | — -16.6K (-100.0%) | — -48.0K (-100.0%) | 0.00% -0.017 pp | 0.00% 0.000 pp | USD— | 2 qtrs SOLD |
| 44 | STATE OF TENNESSEE, TREASURY DEPARTMENT | — -5.1K (-100.0%) | — -14.8K (-100.0%) | 0.00% -0.005 pp | 0.00% +0.000 pp | USD— | 4 qtrs SOLD |
| 45 | TWO SIGMA ADVISERS, LP | — -20.9K (-100.0%) | — -60.5K (-100.0%) | 0.00% -0.021 pp | 0.00% 0.000 pp | USD— | 5 qtrs SOLD |
| 46 | DEUTSCHE BANK AG\ | — -253.4K (-100.0%) | — -732.3K (-100.0%) | 0.00% -0.252 pp | 0.00% 0.000 pp | USD— | 36 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 12 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Invesco NASDAQ Biotech UCITS ETF SBIO.L | 0.02% | 77.4K | 0.40% |
| 2 | Invesco Nasdaq Biotechnology ETF IBBQ | 0.02% | 12.5K | 0.19% |
| 3 | iShares Nasdaq US Biotechnology UCITS ETF BTEC.L | 0.02% | 180.1K | 0.35% |
| 4 | iShares Nasdaq US Biotechnology UCITS ETF BTEE.L | 0.02% | 12.1K | 0.35% |
| 5 | iShares Biotechnology ETF IBB | 0.01% | 1.05M | 0.44% |
| 6 | ProShares Ultra Nasdaq Biotechnology BIB | 0.01% | 8.1K | 1.19% |
| 7 | Dimensional - US Vector Equity ETF DXUV | 0.00% | 8.9K | 0.28% |
| 8 | U.S. Micro Cap Portfolio ETF DFMC | 0.00% | 117.0K | 0.43% |
| 9 | Dimensional - US Small Cap ETF DFAS | 0.00% | 210.1K | 0.26% |
| 10 | Dimensional - US Core Equity 1 ETF DCOR | 0.00% | 15.0K | 0.14% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Ratio by volume
0.00
Bearish
Buys
0
Sells
2
Shares acquired
—
Shares disposed
20.0K
Cash buys
1.00
Cash sales
1.00
Net activity
-20,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-15 | Pfeifer Andrea | Director / Officer | S-Sale | D | Share | 10,000 | 3.14 | 31.4K | 3,830,288 | D | ↗ |
| 2026-03-20 | Donati Piergiorgio | Officer | — | — | Share Option (right to buy) | 34,562 | 6.95 | 240.2K | 0 | D | ↗ |
| 2026-03-18 | Zuegel Martin | Director | — | — | Common Shares | 0 | 0.00 | — | 38,272 | D | ↗ |
| 2026-03-18 | Twyman Roy Ervin | Director | — | — | Share Option (right to buy) | 43,299 | 1.84 | 79.7K | 0 | D | ↗ |
| 2026-03-18 | Roberts Christopher James | Officer | — | — | Share Option (right to buy) | 7,200 | 2.76 | 19.9K | 0 | D | ↗ |
| 2026-03-18 | Pfeifer Andrea | Director / Officer | — | — | Share Option (right to buy) | 102,811 | 9.53 | 979.8K | 0 | D | ↗ |
| 2026-03-18 | June Carl Howard | Director | — | — | Share Option (right to buy) | 43,299 | 1.84 | 79.7K | 0 | D | ↗ |
| 2026-03-18 | Buetler Monika | Director | — | — | Share Option (right to buy) | 14,310 | 5.31 | 76.0K | 0 | D | ↗ |
| 2026-03-18 | AGUIAR-LUCANDER RENEE | Director | — | — | Share Option (right to buy) | 32,061 | 1.84 | 59.0K | 0 | D | ↗ |
Executive team
Top executives
EBIT / Employee
-5.3K
Shares Outstanding
101.77M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Andrea Pfeifer | Co-Founder, Chief Executive Officer & Director | 2M | — |
| Christopher Roberts | Chief Financial Officer & Vice President of Finance | — | male |
| Francesca Capotosti | Senior Vice President of Research | — | — |
| Gary Anthony Waanders | Senior Vice President of Investor Relations & Corporate Communications | — | — |
| Günther Staffler | Executive Vice President of Development | — | — |
| Julien Rongere | Senior Vice President of Regulatory Affairs & Quality Assurance | — | — |
| Mark Danton | Executive Vice President of Information Systems & Artificial Intelligence | — | male |
| Matthias Maurer | Senior Vice President & General Counsel | — | — |
| Oliver Sol | Vice President & Head of Clinical Development | — | — |
| Piergiorgio Donati | Chief Operating Officer | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ACIU
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
